MedTrace Logo

Single-probe Microwave Ablation (MWA) of Metastatic Liver Cancer

NCT00922181 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2009-11-16

No results posted yet for this study

Summary

Microwave ablation (MWA) is the most recent development in the field of local ablative therapies. The aim of this study was to evaluate the variability and reproducibility of single-probe MWA versus radiofrequency ablation (RFA) of metastatic liver tumours smaller than 3 cm in patients without underlying liver disease.

Conditions

  • Liver Neoplasms

Interventions

DEVICE

Microwave ablation

Liver tumors are destructed/ablated using single-probe microwave energy device

DEVICE

Radiofrequency ablation

Liver tumors are destructed/ablated using radiofrequency energy device

Sponsors & Collaborators

  • University Hospital, Gasthuisberg

    lead OTHER

Principal Investigators

  • Baki Topal, MD, PhD · Universitaire Ziekenhuizen KU Leuven

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00922181 on ClinicalTrials.gov